SGLT2i use linked to lower risk for neurodegenerative disease in T2DM
By
HealthDay News
Sep 18, 2024
A reduced risk for Alzheimer’s disease, vascular dementia and Parkinson’s disease was seen with SGLT2i use in type 2 diabetes.
Vision impairment contributes to dementia risk
By
Haymarket Media
Sep 11, 2024
Population-level dementia-attributable fractions from at least one visual impairment were highest among subpopulations of participants aged 71 to 79 years, female individuals and non-Hispanic white individuals,...